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ABSTRACT: The formation of amyloid structures is a neuropathological feature that 
characterizes several neurodegenerative disorders, such as Alzheimer´s and Parkinson´s 
disease. Up to now, the definitive diagnosis of these diseases can only be accomplished 
by immunostaining of post mortem brain tissues with dyes such Thioflavin T and congo 
red. Aiming at early in vivo diagnosis of Alzheimer´s disease (AD), several amyloid-avid 
radioprobes have been developed for b-amyloid imaging by positron emission tomogra-
phy (PET) and single-photon emission computed tomography (SPECT). The aim of this 
paper is to present a perspective of the available amyloid imaging agents, special those 
that have been selected for clinical trials and are at the different stages of the US Food 
and Drugs Administration (FDA) approval.
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Sondas moleculares para a deteção de placas β-amilóide na doença 
de Alzheimer
RESUMO: A formação de estruturas amilóides é uma característica neuropatológica 
comum nas várias doenças neurodegenerativas, como a doença de Alzheimer e de Par-
kinson. Até à data, o diagnóstico destas doenças apenas é conseguido post mortem por 
estudos histoquímicos com corantes, como a Tioflavina T e o vermelho do congo. Du-
rante os últimos anos têm sido desenvolvidos vários compostos com afinidade para 
agregados de ß-amilóide para visualização dessas estruturas por tomografia de emissão 
de positrões (PET) e tomografia computadorizada de emissão de fotão único (SPECT). 
Neste trabalho pretendemos apresentar as principais sondas radioativas com potencial 
para imagiologia de estruturas amilóides, em especial aquelas que entraram em ensaios 
clínicos e se encontram em diferentes etapas de aprovação pela FDA.
Palavras-chave: doença de Alzheimer, agregação da b-amilóide, imagiologia molecular, son-
das moleculares.
Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disorder 
that affects millions of people worldwide1. The impact in 
the public health is considerable, with tendency to increase 
as the population gets older. The most common symptoms 
of AD are decline in the cognitive functions, irreversible 
memory loss, disorientation and language impairment. AD 
diagnosis is based mainly on the patient’s history and on 
neuropsychological tests. However, the overlapping of ear-
ly AD symptoms with normal signs of aging difficults such 
diagnosis. Histopathologically, AD is characterized by the 
presence of senile plaques containing b-amyloid (Ab) 
plaques and neurofibrillary tangles (NFTs) containing highly 
phosphorylated tau protein. Currently, the accurate diag-
nosis of AD is only possible post mortem after confirmation 
of extracellular Ab deposits and NFTs, through histopatho-
logical studies using dyes such as thioflavin T (ThT) and 
congo red (CR)2.
The molecular processes underlying the pathology are still 
unknown, however it is thought that the Aß deposits 
accumulate before the onset of the disease3. Ab is a soluble 
extracellular peptide composed by 40 (Ab1-40) or 42 (Ab1-42) 
aminoacids, which is formed from transmembrane 
amyloid-precursor protein (APP) by the action of b and g 
secretases4. Thus, in vivo imaging agents that can specifi-
cally demonstrate the location and density of Ab deposits 
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6Design of Aβ imaging agents
In the past few years, several compounds have been 
designed to interact with the oligomeric and fibrillar forms 
of the Ab peptide for its in vivo detection5-9. Those com-
pounds are essentially small, aromatic and heteroaromatic 
molecules. Their planarity allows for the insertion into the 
b sheet structure of Ab plaques, ensuring good binding af-
finity. A common requisite for these compounds is the abil-
ity to cross the blood brain barrier (BBB) to reach the intra- 
cerebral target. A good radiotracer for in vivo imaging of 
Ab plaques by PET or SPECT must have a high initial brain 
uptake and a fast washout from the normal brain, to en-
sure a good target/non-target ratio. The design of these 
aromatic and planar compounds for the targeting of Ab 
plaques have been based mainly on the highly conjugated 
system present in the structures of the ThT and CR dyes. So 
far, the most promising SPECT and PET radioprobes for in 
vivo imaging of Ab plaques are compounds containing the 
gamma emitters 123I/125I and the positron emitters 11C or 18F, 
respectively (cf. Figure 2)9. Although 99mTc offers several 
advantages for SPECT imaging, the design of 99mTc-based 
radiopharmaceuticals usually requires a bifunctional chela-
tor (BFC) for the metal complexation. Conjugation of BFCs 
to amyloid-avid molecules produces constructs with limited 
BBB permeability and therefore unsuitable for in vivo 
application. 
in AD brain will be useful for an early and conclusive diag-
nosis of AD (cf. Figure 1). Moreover, these agents will help 
on the finding and monitorization of novel AD therapies, 
especially the ones based on the dissolution of the Ab 
plaques. Positron emission tomography (PET) and single-
photon emission computed tomography (SPECT) are 
among the best suited molecular imaging modalities to 
achieve such a goal. 
Figure 1: In vivo interaction of an imaging probe with cerebral Ab 
plaques.
Figure 2: Chemical structures of relevant Ab imaging agents.
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7Relevant Radiolabeled Aβ imaging probes
Although there are more SPECT than PET scanners, the 
same is not true with respect to agents for amyloid imag-
ing. Among the SPECT amyloid imaging, the 123I-IMPY (cf. 
Figure 2[1]) has shown up as the most promising10, while 
more progress has been observed in the development 
of PET amyloid imaging radioprobes. 123I-IMPY displayed 
selective binding to Ab plaque ex vivo in autoradiographic 
experiments using mice AD model (PSAPP)11. However 
the signal-to-noise ratio for plaque labelling is not ideal, 
maybe due to the fast clearance from the brain and plas-
ma observed in AD and normal subjects12. 
The compound 18F-FDDNP (cf. Figure 2[2]) was the first 
PET probe sucessfully developed for in vivo molecular 
imaging of Ab plaques13. However, PET imaging showed 
that 18F-FDDNP labels both Ab plaques and NFTs in the 
brain of AD, and thus is not selective for measuring Ab 
deposits load in the AD brain. Also, its excessive lipophili- 
city (log P = 3.92) contributed for high non-specific bind-
ing in normal mice brain14. The “Pittsburgh compound B” 
(11C-PIB) (cf. Figure 2[3]) is one of the best characterized 
PET imaging agent for Ab plaques in the brain. It showed 
excellent initial brain uptake and a high binding affinity to 
Ab plaque (Ki = 0.87 ± 0.18 nM)
15. In AD patients, 11C-PIB 
retention, which was increased in the cortical areas, cor-
related inversely with cerebral glucose metabolism deter-
mined with 18F-fluorodeoxyglucose (18F-FDG) (cf. Figure 
3)16. Since then, other studies in thousands of AD patients 
have validated the usefulness of 11C-PIB as a PET Ab 
imaging probe17-20. However, the short half-life of 11C 
(t1/2 = 20 min) limits the clinical use of 
11C-PIB to centers 
with an on-site cyclotron. Such limitation prompted seve- 
ral authors to search for alternative amyloid-binding radio- 
pharmaceuticals labelled with longer lived fluorine-18 
(t1/2 = 110 min). 
18F-Flutemetamol (GE-067) (cf. Figure 2[4]) 
is very similar to PIB, except that it has an 18F-tag instead of 
11C. 3H-Flutemetamol binding reflects Ab deposits load in 
post mortem brain tissue. 18F-Flutemetamol is comparable 
to 11C-PiB in its ability to detect brain Ab pathology in AD 
living patients21. Biopsy and autopsy studies showed that 
18F-flutemetamol has a high specificity and sensitivity in 
the detection of Ab deposits in the brain22. Final Phase III 
data showed a strong concordance between 18F-Flute-
metamol PET imaging and Ab pathology (cf. Figure 4)23. 
A New Drug Application (NDA) was submitted to the US 
Food and Drug Application (FDA) and to European Medi-
cine Agency (EMA) for the use of 18F-flutemetamol in the 
visual detection of Ab burden in adult patients suspected 
of AD24. 
Figure 4: 18F-Flutemetamol images in normal volunteers and in AD 
patients.
The tracers 18F-florbetapen and 18F-florbetapir (cf. Figure 
2[5-6]) were also found to display high-affinity binding to 
Ab plaques with Ki < 10 nM. Thanks to the pyridine ring in 
florbetapir, this tracer is less lipophilic than florbetapen. 
Nonetheless their non-specific binding in white matter 
is higher than that of 11C-PIB25-26. Clinical studies with 
18F-florbetapir demonstrated a strong correlation between 
in vivo amyloid PET imaging and its post mortem his-
topathological binding26. Also, 18F-florbetapir-PET/MR stud-
ies correlated positively the anatomic data with the locali-
zation of 18F-florbetapir retention in the white and gray 
matter often affected by AD. Clinical interpretation of 
18F-florbetapir PET relies upon assessment of gray-white 
differentiation, with negative studies showing higher 
activity in the white matter than in the cerebral cortex (cf. 
Figure 5A) and positive studies showing loss of gray-white 
contrast due to the tracer binding to beta-amyloid plaques 
in the cerebral cortex (cf. Figure 5B)27. 18F-Florbetapir has 
recently been approved by the FDA for clinical use28. None-
theless, other amyloid PET tracers are in late phase clinical 
trials and may soon become clinically available. 
Figure 3: 11C-PIB standardized uptake value (SUV) and 18FDG rCMRglc 
images in AD patients and healthy control (HC) subjects13. Reproduced 
by permission of John Wiley and Sons.
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8Figure 5: Amyloid imaging with 18F-florbetapir. A) Normal control subject with no-to-sparse Ab plaques. B) Positive PET/MRI study, consistent 
with moderate to frequent Ab plaques20. 
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Conclusions
The 11C-PIB, 18F-flutemetamol, 18F-florbetapen, and 
18F-florbetapir have been well studied in humans as amy-
loid imaging agents. The imaging performance of these 
four PET tracers is comparable with high retention in corti-
cal regions, providing all of them good contrast with 
non-target regions. Despite being the best studied, 11C-PIB 
has not been yet approved by the FDA, while 18F-flute-
metamol is pending FDA and EMA approval. So far, the 
only amyloid PET tracer authorized by the FDA is the 
18F-florbetapir (Amyvid) for brain imaging of cognitively 
impaired adults undergoing evaluation of AD28. 
Acknowledgments
We thank the Fundação para a Ciência e Tecnologia (FCT) 
– PTDC/QUI/102049/2008 and "Ciência 2008" program – 
for financial support.
References
1. Alzheimer Association. 2012 Alzheimer’s disease facts and 
figures. Alzheimers Dement. 2012;8(2):131-68.
2. Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang 
GF, et al. Four-dimensional multiphoton imaging of brain 
entry, amyloid binding, and clearance of an amyloid-beta 
ligand in transgenic mice. Proc Natl Acad Sci U S A. 
2003;100 (21):12462-7.
SAÚDE & TECNOLOGIA . NOVEMBRO | 2013 | #10 | P. 5-9 . ISSN: 1646-9704
9pyridines as ligands for detecting beta-amyloid plaques in 
the brain. J Med Chem. 2003;46(2):237-43.
11. Kung MP, Hou C, Zhuang ZP, Cross AJ, Maier DL, Kung HF. 
Characterization of IMPY as a potential imaging agent for 
beta-amyloid plaques in double transgenic PSAPP mice. 
Eur J Nucl Med Mol Imaging. 2004;31(8):1136-45.
12. Newberg AB, Wintering NA, Plössl K, Hochold J, Stabin 
MG, Watson M, et al. Safety, biodistribution, and dosime-
try of 123I-IMPY: a novel amyloid plaque-imaging agent 
for the diagnosis of Alzheimer's disease. J Nucl Med. 
2006;47(5):748-54.
13. Barrio J, Huang S, Cole G, Satyamurthy N. PET imaging of 
tangles and plaques in Alzheimer's disease with a highly 
hydrophobic probes. J Labelled Comp Radiopharm. 1999; 
42(Suppl 11):S194-S5.
14. Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, 
Petric A, et al. Binding characteristics of radiofluorinated 
6-dialkylamino-2-naphthylethylidene derivatives as posi-
tron emission tomography imaging probes for beta-
amyloid plaques in Alzheimer's disease. J Neurosci. 
2001;21(24):RC189.
15. Mathis CA, Wang YM, Holt DP, Huang GF, Debnath ML, 
Klunk WE. Synthesis and evaluation of C-11-labeled 
6-substituted 2-arylbenzothiazoles as amyloid imaging 
agents. J Med Chem. 2003;46(13):2740-54.
16. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, 
Holt DP, et al. Imaging brain amyloid in Alzheimer's disease 
with Pittsburgh Compound-B. Ann Neurol. 2004;55(3): 
306-19.
17. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, 
et al. Imaging beta-amyloid burden in aging and dementia. 
Neurology. 2007;68(20):1718-25. 
18. Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Sax-
ton JA, et al. Characterizing regional correlation, laterality 
and symmetry of amyloid deposition in mild cognitive im-
pairment and Alzheimer's disease with Pittsburgh Com-
pound B. J Neurosci Methods. 2008;172(2):277-82.
19. Butters MA, Klunk WE, Mathis CA, Price JC, Ziolko SK, 
Hoge JA, et al. Imaging Alzheimer pathology in late-life 
depression with PET and Pittsburgh compound-B. Alzhei-
mer Dis Assoc Disord. 2008;22(3):261-8.
20. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman 
T, et al. Amyloid load and cerebral atrophy in Alzheimer's 
disease: an C-11-PIB positron emission tomography study. 
Ann Neurol. 2006;60(1):145-7.
21. Ikonomovic M, Price J, Abrahamson E, Mathis C, Paljug W, 
Debnath M, et al. Direct correlations of [H-3]flutemetamol 
binding with [H-3]PiB binding and amyloid-beta concen-
tration and plaque load in [C-11]PiB imaged brains. Neuro-
logy. 2012;78(Meeting Abstracts 1):S34.002.
22. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin 
C, Triau E, et al. 18F-flutemetamol amyloid imaging in Al-
zheimer disease and mild cognitive impairment: a phase 2 
trial. Ann Neurol. 2010;68(3):319-29.
23. Wolk D, Gomez J, Sadowsky C, Singh U, Rinne J, Wong D, 
et al. Brain autopsy and in-vivo cortical brain biopsy trials 
show a strong concordance between [F-18]flutemetamol 
PET and amyloid-beta pathology. Neurology. 2012; 
79(11):E88.
24. Express Healthcare. US FDA, EMEA accept GE healthcare's 
review applications for [18F] flutemetanol [Internet]. Ex-
press Healthcare; 2013 Jan 9. Available from: http://health-
care.financialexpress.com/latest-updates/1166-us-fda-
emea-accept-ge-healthcare-s-review-applications-for-18f-
flutemetamol
25. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buer-
ger K, et al. Cerebral amyloid-beta PET with florbetaben 
(18F) in patients with Alzheimer’s disease and healthy con-
trols: a multicentre phase 2 diagnostic study. Lancet Neu-
rol. 2011;10(5):424-35.
26. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, 
Mintun MA, et al. Use of florbetapir-PET for imaging beta-
amyloid pathology. JAMA. 2011;305(3):275-83.
27. Fowler K, McConathy J, Khanna G, Dehdashti F, Benzinger 
TL, Miller-Thomas M, et al. Simultaneous PET/MRI acquisi-
tion: clinical potential in anatomically focused and whole-
body examinations. Appl Radiol. 2013;42(6):9-14.
28. Yang L, Rieves D, Ganley C. Brain amyloid imaging – FDA 
approval of Florbetapir F18 Injection. New Engl J Med. 
2012;367(10):885-7.
Artigo recebido em 07.08.2013
SAÚDE & TECNOLOGIA . NOVEMBRO | 2013 | #10 | P. 5-9 . ISSN: 1646-9704
